Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT03643367
PHASE2

Sevoflurane Sedation in Patients With Septic Shock

Sponsor: University of Zurich

View on ClinicalTrials.gov

Summary

Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery. Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.

Official title: Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

153

Start Date

2026-01

Completion Date

2027-11

Last Updated

2025-04-01

Healthy Volunteers

No

Conditions

Interventions

DRUG

Sevoflurane

Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.

DRUG

Control Group

Included patients randomized in control group, intravenouse sedation is continued with propofol

Locations (4)

Kantonasspital Münsterlingen

Münsterlingen, Switzerland

Stadtspital Triemli

Zurich, Switzerland

University Hospital of Zurich

Zurich, Switzerland

Waidspital Zürich

Zurich, Switzerland